Europe Cervical Cancer Test Market: By Test Type (Colposcopy, Pap smear tests, Endocervical curettage, Human Papilloma Virus (HPV) testing, Visual Inspection with Acetic acid (VIA) testing, Others), By End User (Hospitals, Oncology centers, Diagnostic Centres) and Country Forecast 2020-2031

Europe Cervical Cancer Test Market size was valued at US$ X million in 2024 and is expected to reach US$ X million by 2031, growing at a significant CAGR of X% from 2025-2031. Europe market is growing at a significant CAGR owing to technological advancements in cervical cancer diagnostic equipment and procedures. Changes in lifestyles such as smoking, unsafe sex, and high adoption of technologically advanced diagnostic tests are anticipated to fuel the European cervical cancer test market. Amongst countries, Germany has the highest cervical cancer screening test. For instance, a total number of tests for cervical cancer done in the Germany in 2023 was 15,334,344 and is expected to be 15,589,559 in 2030, amongst which pap smear tests were 74.6%, HPV tests were 20.4% and LBC tests were 4.9%. 

Moreover, government initiatives for creating awareness about cervical cancer diagnostic tests and an increase in R&D investment for the innovation of novel technologies are also expected to propel the European cervical cancer test market over the forecast period. However, an increase in the prevalence of cervical cancer in Europe region expected to drive the Europe market. For instance, according to the International Agency for Research on Cancer 2012, the incidence rate of cervical cancer is 13.4 per 100,000 people and the mortality rate is 4.9 per 100,000 people.

However, mortality is decreasing owing to an increase in technological advancements in disease diagnostics and the launching of low-cost tests such as the Visual Inspection with Acetic acid (VIA) test. Moreover, acquisitions mergers, and diversification of business segments are the strategies followed by the market players to increase their revenue in Europe's cervical cancer test market. For instance, in July 2011, Roche acquired mtm Laboratories AG for the expansion of the Cervical Cancer Test Market in the Europe region. According to the World Health Organization Europe, approximately 28,000 women die from cervical cancer every year in the Europe region. The prevalence rate is higher in Germany, France, and the U.K. (according to Cancer Research UK 2014, about 3,224 new cervical cancer cases were diagnosed in the U.K.).